Biomedical HIV Prevention Trials: Results, milestones and more

This graphic shows the updated status of large-scale prevention trials through 2022 and the impact of COVID-19 on each trial.

Another version of this graphic is available here (same content, different visual Treatment U=U).

Public Comment from Mitchell Warren, Executive Director, AVAC At the Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting

Comments made by Mitchell Warren to the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting on October 22, 2020 about COVID-19 vaccine development and use authorization.

The Next-Generation of Biomedical Prevention: Now What

Slides presented by AVAC Executive Director Mitchell Warren at the PEPFAR Scientific Advisory Board meeting taking place over October 7-8, 2020.

Understanding the EMA Opinion and Next Steps for the Dapivirine Vaginal Ring

On July 24, 2020, the European Medicines Agency (EMA) announced a positive regulatory opinion from on the Dapivirine Vaginal Ring as an HIV prevention option for cisgender women age 18 and older. This document helps advocates to understand the steps that can and must be taken now that the EMA has provided its opinion. Read it here.

Global Investment in HIV Cure Research and Development in 2019

In 2014, the HIV Vaccines and Microbicides Resource Tracking Working Group and AVAC began a

Regulatory Approval Primer for Vaccine Advocates

The difference between speed and cutting corners can be one of life or death for individuals, and of impact versus impasse for societies. Advancing a vaccine candidate without peer-reviewed research results and thorough regulatory review can also undermine confidence in public institutions and vaccines generally. Global health advocates have an essential role to play as watchdogs of the regulatory systems that have worked well for decades, but may be vulnerable to global pressure for a vaccine and the current politicization of science.

COVID-19 Vaccine Pipeline PowerPoint Presentation

This set of slides offers advocates a view of the funders, platforms, research phase and considerations for some of the front-runner candidates.

Cheat Sheet: COVID-19 Vaccine Pipeline

This three-pager offers advocates an at-a-glance view of the funders, platforms, research phase and considerations for some of the front-runner candidates.

Research Fundamentals: What is partial protection?

AVAC is launching a new series on our podcast Px Pulse—Research Fundamentals. In addition to our regular schedule of programs covering advances and challenges in HIV prevention research, Research Fundamentals we’ll explore scientific concepts in research, one at a time.

In our debut episode we explore the concept of partial protection, with:

  • David Evans, science and advocacy consultant for AVAC, formerly of Project Inform
  • Penny Moore from South Africa’s University of the Witwatersrand and National Institute for Communicable Diseases
  • And Sandhya Vasan of the US Military HIV Research Program

Together we explore the meaning of partial protection. Whether it’s condoms, a flu shot, oral PrEP or the dapivirine vaginal ring, proven products fall short of 100 percent protection against disease, and there’s a lot to know about how and why an intervention may offer imperfect but still useful protection.

Listen

Integration of HIV prevention and SRH services in Zimbabwe

Findings from an assessment of HIV prevention and SRH integration in Zimbabwe, conducted in collaboration with the Ministry of Health and Child Care, comprised of site visits to health facilities, key informant interviews, civil society dialogues and a policy review.